Fund size | GBP 60 m |
Total expense ratio | 0.49% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in GBP) | 18.73% |
Inception/ Listing Date | 2 July 2019 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | Legal & General (LGIM) |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
Investment Advisor | Legal & General Investment Management Limited |
Custodian Bank | BNY Mellon Trust Company (Ireland) Limited |
Revision Company | EY |
Fiscal Year End | 30 June |
Swiss representative | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Swiss paying agent | State Street Bank International GmbH, München, Zweigniederlassung Zürich |
Germany | 30% tax rebate |
Switzerland | No ESTV Reporting |
Austria | Tax Reporting Fund |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | BNY Mellon Fund Services (Ireland) Limited |
Securities lending | No |
Securities lending counterparty |
Azenta | 2.18% |
Arrowhead Pharmaceuticals | 2.13% |
iRhythm Technologies | 2.08% |
Illumina | 2.08% |
Moderna, Inc. | 2.03% |
Intuitive Surgical | 2.01% |
Catalent | 1.99% |
Stryker | 1.91% |
Revvity | 1.90% |
Lonza Group AG | 1.85% |
United States | 81.25% |
Switzerland | 4.61% |
Italy | 1.65% |
Netherlands | 1.64% |
Other | 10.85% |
Health Care | 93.87% |
Technology | 1.29% |
Consumer Discretionary | 0.89% |
Basic Materials | 0.80% |
Other | 3.15% |
YTD | +2.19% |
1 month | +1.53% |
3 months | +1.41% |
6 months | +8.75% |
1 year | -3.02% |
3 years | -27.53% |
5 years | - |
Since inception (MAX) | +19.49% |
2023 | -8.06% |
2022 | -25.30% |
2021 | +1.45% |
2020 | +60.22% |
Volatility 1 year | 18.65% |
Volatility 3 years | 25.15% |
Volatility 5 years | - |
Return per risk 1 year | -0.33 |
Return per risk 3 years | -0.42 |
Return per risk 5 years | - |
Maximum drawdown 1 year | -26.64% |
Maximum drawdown 3 years | -49.73% |
Maximum drawdown 5 years | - |
Maximum drawdown since inception | -51.17% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | XMLH | - - | - - | - |
Borsa Italiana | EUR | DOCT | DOCT IM DOCEURIV | DOCT.MI DOCTEURINAV=SOLA | Flow Traders B.V. |
London Stock Exchange | GBX | DOCG | DOCG LN NA | DOCG.L NA | Flow Traders B.V. |
London Stock Exchange | USD | DOCT | DOCT LN NA | DOCT.L NA | Flow Traders B.V. |
SIX Swiss Exchange | CHF | DOCT | DOCT SW DOCEURIV | DOCT.S | Flow Traders B.V. |
XETRA | EUR | XMLH | XMLH GY DOCEURIV | DOCT.DE | Flow Traders B.V. |
Fund name | Fund Size in m € (AuM) | TER in % p.a. | Distribution policy | Replication method |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 1,056 | 0.40% p.a. | Accumulating | Sampling |
L&G Pharma Breakthrough UCITS ETF | 20 | 0.49% p.a. | Accumulating | Full replication |
HANetf HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF | 16 | 0.59% p.a. | Accumulating | Full replication |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 7 | 0.35% p.a. | Accumulating | Full replication |
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 3 | 0.30% p.a. | Accumulating | Full replication |